Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats

Hepatology

Volumn 44, Issue 4, 2006, Pages 983-991

  Kitade, Mitsuteru ^a   Yoshiji, Hitoshi ^a   Kojima, Hideyuki ^a   Ikenaka, Yasuhide ^a   Noguchi, Ryuichi ^a   Kaji, Kosuke ^a   Yoshii, Junichi ^a   Yanase, Koji ^a   Namisaki, Tadashi ^a   Asada, Kiyoshi ^a   Yamazaki, Masaharu ^a   Tsujimoto, Tatsuhiro ^a   Akahane, Takemi ^a   Uemura, Masahito ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYGUANOSINE; CD31 ANTIGEN; GLUTATHIONE TRANSFERASE P1; GUANOSINE DERIVATIVE; LEPTIN; LEPTIN RECEPTOR; THIOBARBITURIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN; CHOLINE; GSTP1 PROTEIN, RAT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FIBROGENESIS; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALE; NEOVASCULARIZATION (PATHOLOGY); NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DIET; RAT; ANIMAL; DISEASE MODEL; FATTY LIVER; FIBROSIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; ZUCKER RAT;

ANIMALS; ANTIGENS, CD31; CARCINOMA, HEPATOCELLULAR; CHOLINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; FIBROSIS; GLUTATHIONE S-TRANSFERASE PI; LEPTIN; MALE; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; RATS; RATS, ZUCKER; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33750607736     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21338     Document Type: Article

References (45)

1. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
2. Ludwig J, Viggiano TR, McGill D, Ott B. Non-alcoholic Steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
3. Reid AE. Non-alcoholic steatohepatitis. Gastroenterology 2001;121:710-723.
4. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. HEPATOLOGY 2002;36:1349-1354.
5. Day CP, James OF. Steatohepatitis: a tale of rwo "hits"? Gastroenrerology 1998;114:842-845.
6. Pessayre D, Mansouri A, Fromenty B. Non-alcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002;282:G193-G199.
7. Gao D, Wei C, Chen L, Huang J, Yang S, Diehl AM. Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 287:G1070-G1077.
8. Seki S, Kitada T, Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol Res 2005; 33:132-134.
9. Nanji AA. Animal models of non-alcoholic fatty liver disease and steatohepatitis. Clin Liver Dis 2004;8:559-574.
10. Nakae D, Yoshiji H, Mizumoto Y, Horiguchi K, Shiraiwa K, Tamura K, et al. High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Res 1992;52:5042-5045.
11. Carmiel-Haggai M, Cederbaum AI, Nieto N. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 2005;19:136-138.
12. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37:206-213.
13. Honda H, Ikejima K, Hirose M, Yoshikawa M, Lang T, Enomoto N, et al. Leptin is required for fibrogenic responses induced by thioacetamide in the mutine liver. HEPATOLOGY 2002;36:12-21.
14. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002;122: 1399-1410.
15. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
16. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.
17. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003;52:1347-1354.
18. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, et al. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. HEPATOLOGY 2004;39: 1517-1524.
19. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407:242-248.
20. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001;26:25-35.
21. Huang L, Li C. Leptin: a multifunctional hormone. Cell Res 2000;10:81-92.
22. Jin X, Fukuda N, Su J, Takagi H, Lai Y, Lin Z, et al. Effects of leptin on endothelial function with OB-Rb gene transfer in Zucker fatty rats. Atherosclerosis 2003;169:225-233.
23. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, et al. Biological action of leptin as an angiogenic factor. Science 1998;281:1683-1686.
24. Lerman OZ, Galiano RD, Armour M, Levine JP, Gurtner GC. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol 2003;162:303-312.
25. Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, Cao Y. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci U S A 2001;98:6390-6395.
26. Nakae D, Mizumoto Y, Yoshiji H, Andoh N, Horiguchi K, Shiraiwa K, et al. Different roles of 8-hydroxyguanine formation and 2-thiobarbituric acid-reacting substance generation in the early phase of liver carcinogenesis induced by a choline-deficient, L-amino acid-defined diet in rats. Jpn J Cancer Res 1994;85:499-505.
27. Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 1999;49:91-102.
28. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, et al. The copper-chelating agent, trientine, attenuates liver enzyme-altered preneoplastic lesions in rats by angiogenesis suppression. Oncol Rep 2003;10: 1369-1373.
29. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001;7:1073-1078.
30. Saito M, Hamasaki M, Shibuya M. Induction of tube formation by angiopoietin-1 in endothelial cell/fibroblast co-culture is dependent on endogenous VEGF. Cancer Sci 2003;94:782-790.
31. Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA, et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000; 378:259-268.
32. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. HEPATOLOGY 2002;35:762-771.
33. Ikejima K, Okumura K, Lang T, Honda H, Abe W, Yamashina S, et al. The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res 2005;33:151-154.
34. Park YN, Yang CP, Fernandez GJ, Cubukcu O, Thung SN, Theise ND. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol 1998;22:656-662.
35. Schaffner F, Poper H. Capillarization of hepatic sinusoids in man. Gastroenterology 1963;44:239-242.
36. Kalluri R, Sukhatme VP. Fibrosis and angiogenesis. Curr Opin Nephrol Hypertens 2000;9:413-418.
37. Frankenberry KA, Somasundar P, McFadden DW, Vona-Davis LC. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 2004;188:560-565.
38. Gealekman O, Brodsky SV, Zhang F, Chander PN, Friedli C, Nasjletti A, et al. Endothelial dysfunction as a modifier of angiogenic response in Zucker diabetic fat rat: amelioration with Ebselen. Kidney Int 2004;66: 2337-2347.
39. Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, et al. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut 2005;54:1768-1775.
40. Somasundar P, Yu AK, Vona-Davis L, McFadden DW. Differential effects of leptin on cancer in vitro. J Surg Res 2003;113:50-55.
41. Elinav E, Abd-Elnabi A, Pappo O, Bernstein I, Klein A, Engelhardt D, et al. Suppression of hepatocellular carcinoma growth in mice via leptin, is associated with inhibition of tumor cell growth and natural killer cell activation. J Hepatol 2006;44:529-536.
42. Wang XJ, Yuan SL, Lu Q, Lu YR, Zhang J, Liu Y, et al. Potential involvement of leptin in carcinogenesis of hepatocellular carcinoma. World J Gastroenterol 2004;10:2478-2481.
43. Yang S, Lin HZ, Hwang J, Chacko VP, Diehl AM. Hepatic hyperplasia in non-cirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 2001;61:5016-5023.
44. Sakaida I, Hironaka K, Uchida K, Suzuki C, Kayano K, Okita K. Fibrosis accelerates the development of enzyme-altered lesions in the rat liver. HEPATOLOGY 1998;28:1247-1252.
45. Okita K, Sakaida I, Hino K. Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 2002;62(Suppl 1):24-28.